Zim Laboratories Limited — PPTs, 20-05-2025: Investor Presentation

1. Financial Highlights:

ZIM Laboratories reported total operating income of ₹379 Cr, up 3.2% YoY, led by export growth of 8.9% to ₹312.5 Cr, which accounted for 82% of revenue. EBITDA rose 6.4% YoY to ₹49.5 Cr with margins expanding to 13.1%. However, PAT declined to ₹12.2 Cr owing to higher finance costs (₹11.4 Cr) and depreciation (₹20.1 Cr). Q4 showed strong quarter-on-quarter growth: revenue +12.9% to ₹108.7 Cr, EBITDA +22.6% to ₹16.3 Cr, and PAT +22.1% to ₹4.9 Cr. The balance sheet remains solid with net worth at ₹252.2 Cr and stable gearing of 44%, supporting ongoing expansion.

2. Strategic Initiatives & Growth Drivers:

ZIM invested ₹36.5 Cr in capex, completing two manufacturing projects—Urology NIP and Liquid in Pellet technology—to enhance innovative product capacity. ₹10.3 Cr funded bioequivalence studies and regulatory filings. R&D spend was ₹33.3 Cr (8.8% of revenue), driving product development and scale-up. Innovative products (New Innovative Products + Oral Thin Films) grew 68% YoY to ₹62.4 Cr, contributing 19% of revenues; dossier licensing added ₹9.8 Cr.

3. Business Developments:

Expansion continued via the Australian subsidiary and a new Middle East Scientific Office to boost regulatory filings and market reach. A tech-out licensing deal for Oral Thin Films in UAE, along with a partnership with Globalpharma Co. LLP for GCC commercialization, strengthens regional presence. Business development teams enhanced focus across MENA, Australia, and emerging markets.

4. Market Position & Competitive Advantage:

ZIM’s edge stems from cutting-edge technology platforms and a strong R&D pipeline with 23 New Innovative Product filings and 17 Oral Thin Film filings scheduled FY25, plus multiple EU approvals. Its emphasis on high-value, innovative formulations and global expansion through subsidiaries and partnerships supports differentiation and scalability in regulated markets.

5. Investor Implications:

Steady revenue growth fueled by innovation and global expansion indicates positive growth potential. Margin improvement and capex in manufacturing infrastructure bode well for execution. Investors should watch for execution risks linked to geopolitical issues and rising finance costs but can be optimistic about the company’s focus on higher-margin innovative products and expanding international footprint.